Covid19
Conditions
Keywords
antiviral, SARS-CoV-2, COVID19
Brief summary
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients with Mild COVID-19
Interventions
BIOLOGICALNovaferon
a novel recombinant antiviral protein drug
BIOLOGICALPlacebo
Saline
Sponsors
Tokyo Shinagawa Hospital
Genova Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written informed consent has been obtained from the participants with an age of over 20 years at the time of signing the informed consent. 2. SARS-CoV-2 infection is diagnosed by RT-PCR within 72 hours before starting drug administration. 3. Less than six days from onset of COVID-19-related symptoms below to starting the administration of the investigational drug with at least one of the following symptoms observed at the time of enrollment : fever (37.5C or higher), respiratory symptoms (cough, shortness of breath, sore throat, runny nose, etc.), headache, myalgia, malaise, abdominal pain, diarrhea, nausea/vomiting, dysosmia, dysgeusia, or other COVID-19 symptoms defined by investigators or coinvestigators investigators. 4. Oxygen saturation (SpO2) measured by pulse oximeter is more than 95%. 5. Require no supplemental oxygen. 6. Women (less than 12 months after the last menstrual period) who have a negative pregnancy test (urine hCG qualification) and agree to use highly effective contraceptive methods (taking oral contraceptives or use of condom by male partner) during the study period. Investigators or coinvestigators investigators will provide guidance on contraceptive methods. 7. Women who are not breast-feeding.
Exclusion criteria
1. History of hypersensitivity to interferon or JH509 or any excipients of interferon or JH509. 2. Have received antiviral treatments and drugs expected to have antiviral effects (Favipiravir, Remdesivir, Interferon, Nafamostat mesilate, and Basiliximab/Imdevimab, including drugs that are being newly developed and that have been approved) in the past or having had it considered necessary to receive these treatments during the study period. 3. Having had it considered necessary to receive treatments, such as drugs containing corticosteroids (excluding topical drugs), antimicrobial agents, and inhalants other than the investigational drug during the study period. 4. Taking Shosaikoto, an herbal medicine. 5. Neuropsychiatric disorder and autoimmune disorder. 6. CTCAE Grade 3 or higher liver dysfunction (ALT/AST \> 5ULN) or renal dysfunction (eGFR \< 30 mL/min/1.73 m2). 7. Active infections or other medical conditions that contraindicate inhalation therapy. 8. Having the complication of malignant tumor or a history of malignant tumor within 1 year before consent acquisition. 9. Inappropriate for inclusion in the clinical trial as determined by investigators or coinvestigators investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of severe conditions with Score 3 or more serious on a seven-point ordinal scale from the start date of investigational drug administration (Day 1) to Day 28. | 28 day |
Countries
Japan
Contacts
Primary ContactMasaharu Shinkai
Backup ContactHaifeng Jin
Outcome results
None listed